	US 12,435,313 B2
	Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors
Timothy Joseph Kamp, Madison, WI (US); and Pratik Arvind Lalit, Madison, WI (US)
Assigned to Wisconsin Alumni Research Foundation, Madison, WI (US)
Filed by Wisconsin Alumni Research Foundation, Madison, WI (US)
Filed on Jun. 30, 2022, as Appl. No. 17/855,379.
Application 17/855,379 is a continuation of application No. 14/542,280, filed on Nov. 14, 2014, granted, now 11,377,639.
Claims priority of provisional application 61/904,881, filed on Nov. 15, 2013.
Prior Publication US 2023/0038168 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/077 (2010.01)

CPC C12N 5/0657 (2013.01) [C12N 5/0661 (2013.01); C12N 2501/06 (2013.01); C12N 2501/415 (2013.01); C12N 2501/60 (2013.01); C12N 2506/1307 (2013.01)]

7 Claims

1. An isolated induced cardiac progenitor cell (iCPC) comprising one or more copies of one or more episomal vectors encoding five reprogramming factors of Mesp1, Baf60c, Nkx2.5, Gata4, and Tbx5, wherein the isolated iCPC is capable of differentiating into cardiomyocytes, SM-MHC⁺ smooth muscle cells, and CD31⁺ endothelial cells,

wherein the iCPC is capable of proliferating and remaining multipotent for at least 5 passages in a culture medium comprising an activator of canonical Wnt signaling and an activator of Jak/Stat signaling, and